Validation of a General in Vitro Approach for Prediction of Total Lung Deposition in Healthy Adults for Pharmaceutical Inhalation Products

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 6, 2013, Pages 355-369

  Olsson, Bo ^a   Borgström, Lars ^a   Lundbäck, Hans ^a   Svensson, Marten ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b EMMACE Consulting AB   (Sweden)

Author keywords

Dry powder inhaler; In vitro; Inhalation; Lung deposition; Nebulizer; Prediction; Pressurized metered dose inhaler; Throat cast; Validation

Indexed keywords

AZD 4818; BUDESONIDE; CHEMOKINE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRY POWDER INHALER; FEMALE; FILTER; FILTRATION; FLOW RATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATION; INHALATION SPACER; LUNG DEPOSITION; LUNG FUNCTION; MALE; METERED DOSE INHALER; NEBULIZER; NORMAL HUMAN; PEAK INSPIRATORY FLOW; PREDICTION; RANDOMIZED CONTROLLED TRIAL; THROAT; VALIDATION PROCESS;

ADMINISTRATION, INHALATION; ADULT; BIOLOGICAL AVAILABILITY; BUDESONIDE; CROSS-OVER STUDIES; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; METERED DOSE INHALERS; MODELS, ANATOMIC; PHARYNX; PIPERIDINES; REPRODUCIBILITY OF RESULTS; SPIRO COMPOUNDS;

EID: 84883867470     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0986     Document Type: Article

References (24)

1. Newman S, and Chan H: In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Del. 2008;21:1-8.
2. Delvadia RR, Longest PW, and Byron PR: In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm Drug Del. 2012;25:32-40.
3. Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, Olsson B, Thiel CG, Wachtel H, and Finlay WH: In vitro-in vivo correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Del. 2010;23(S2):S59-S69.
4. Van Oort M, Gollmar RO, and Bohinski RJ: Effects of sampling chamber volume and geometry on aerodynamic size distributions of metered-dose inhalation aerosols measured with the Andersen Cascade Impactor. Pharm Res. 1994;11:604-607. (Pubitemid 24144460)
5. Swift DL: Apparatus and method for measuring regional distribution of therapeutic aerosols and comparing delivery systems. J Aerosol Sci. 1992;23:S495-S498.
6. Olsson B: Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8:S13-S19.
7. Olsson B, Borgstrom L, Asking L, and Bondesson E: Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: RN Dalby, PR Byron, and SJ Farr, (eds). Respiratory Drug Delivery V. Interpharm Press Inc., Buffalo Grove, AZ; pp. 273-281, 1996.
8. Olsson B, Berg E, and Svensson M: Comparing aerosol size distribution that penetrates mouth-throat models under realistic inhalation conditions. In: RN Dalby, PR Byron, J Peart, J Suman, and P Young, (eds). Respiratory Drug Delivery 2010. Davis Healthcare, River Grove, IL; pp. 225-234, 2010.
9. Pritchard S, and McRobbie D: Studies of the human oropharyngeal airspaces using magnetic resonance imaging. II. The use of three-dimensional gated MRI to determine the influence of mouthpiece diameter and resistance of inhalation devices on the oropharyngeal airspace geometry. J Aerosol Med. 2004;17:310-324. (Pubitemid 40116948)
10. Grgic B, Heenan AF, and Finlay WH: In vitro intersubject and intrasubject deposition measurement in realistic mouth-throat geometries. J Aerosol Sci. 2004;35:1025-1040. (Pubitemid 38993745)
11. Burnell PKP, Asking L, Borgström L, Nichols SC, Olsson B, Prime D, and Shrubb I: Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV-The oropharyngeal retention effect for four inhalation delivery systems. J Aerosol Med. 2007;20:269-281. (Pubitemid 47463183)
12. Olsson B, Borgström L, Svensson M, and Lundbäck H: Modeling oropharyngeal cast deposition to predict lung delivery from powder inhalers. In: RN Dalby, PR Byron, J Peart, JD Suman, S Farr, and PM Young, (eds). Respiratory Drug Delivery X. Davis Healthcare International Publishing, LLC, River Grove, IL; pp. 197-205, 2008.
13. Kerstjens HA, Bjermer L, Eriksson L, Dahlström K, and Vestbo J: Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir Med. 2010;104:1297-1303.
14. Olsson B, and Asking L: A model for the effect of inhalation device flow resistance on the peak inspiratory flow rate and its application in pharmaceutical testing. J Aerosol Med. 1994;7:201-204. (Pubitemid 24290035)
15. Miller NC, Maniaci MJ, Dwivedi S, and Ward GW: Aerodynamic sizing with simulated inhalation profiles: total dose capture and measurement. In: RN Dalby, PR Byron, SJ Farr, and J Peart, (eds). Respiratory Drug Delivery VII. Serentec Press, Raleigh, NC; pp. 191-196, 2000.
16. Olsson B, and Asking L: Methods of setting and measuring flow rates in pharmaceutical impactor experiments. Pharm Forum. 2003;29:879-884.
17. Borgström L, and Nilsson M: A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 1990;7:1068-1070. (Pubitemid 20366736)
18. Thorsson L, Edsbäcker S, and Conradson T: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839-1844. (Pubitemid 24337357)
19. Bredberg U, Karlsson M, and Borgstrom L: A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther. 1992;52:239-248.
20. Zhang Y, Gilbertson K, and Finlay WH: In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med. 2007;20:227-235. (Pubitemid 47463180)
21. NCRP (National Council on Radiation Protection and Measurements). Deposition, retention and dosimetry of inhaled radioactive substances. NCRP Report 125, Bethesda, MD; 1997.
22. Leach C: Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250-S252. (Pubitemid 30005008)
23. Wachtel H, Bickman D, Breitkreuz J, and Langguth P: Can pediatric throat models and air flow profiles improve our dose finding strategy? In: RN Dalby, PR Byron, J Peart, J Suman, and P Young, (eds). Respiratory Drug Delivery 2010. Davis Healthcare, River Grove, IL; pp. 195-204, 2010.
24. Golshahi L, and Finlay WH: An idealized child throat that mimics average pediatric oropharyngeal deposition. Aerosol Sci Technol. 46(5):i-iv, 2012.